Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction:

Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than simply suppress inflammation.

Why was this article needed?

Current therapies effectively control inflammation but rarely correct the underlying immune dysfunction. Cellular immunotherapy offers the potential for durable remission through immune reprogramming.

• Stem Cell Therapy: Haematopoietic and mesenchymal stem cells have shown encouraging results in refractory IBD by promoting immune regulation and tissue repair. However, larger clinical trials are needed to establish long-term safety and efficacy.
• Regulatory T-Cell Therapy: Engineered regulatory T (Treg) cells aim to restore immune tolerance through targeted anti-inflammatory effects rather than broad immunosuppression. Early clinical trials are evaluating their safety and therapeutic potential.
• Tr1 Cell Therapy: IL-10-producing type 1 regulatory T (Tr1) cells may suppress intestinal inflammation and promote long-term immune regulation. Early-stage clinical studies are currently in progress.
• CAR T-Cell Therapy: A recent case report demonstrated sustained remission of ulcerative colitis following CD19-targeted CAR T-cell therapy, suggesting an important pathogenic role for B cells and opening a promising new therapeutic strategy.
• CAR Treg Therapy: CAR Treg cells combine antigen-specific targeting with immune regulation, providing precise control of intestinal inflammation while preserving normal immune function.

Clinical Impact:

Engineered cellular therapies could transform the management of refractory IBD, particularly in patients with multiple biologic failures. However, these therapies remain investigational and require validation in well-designed prospective clinical trials.

Bottom Line:

Stem cells, Tregs, Tr1 cells, and CAR T-cell platforms represent the next generation of IBD therapy, with the potential to restore immune tolerance and achieve durable disease modification beyond conventional immunosuppression.